THSD7B

Across TCGA pan-cancer cohorts, THSD7B Mutation is linked to patient survival in 10 of 34 cancer types, making it a survival-associated THSD7B data layer compared with 25 for mass-spec protein.

The strongest signal is observed in pheochromocytoma and paraganglioma (PCPG), where higher THSD7B Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated THSD7B expression acts as an unfavorable survival marker, although some lineages such as LUSC and SKCM show a favorable association.

PCPG, CESC, and SCLC are the cancer types where THSD7B Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PCPG	OS	Median	All	0.032	0.948	<.001	12	view →
CESC	OS	Median	IV	0.121	0.591	.029	12	view →
SCLC	DFS	Median	All	0.223	0.610	<.001	9	view →
BRCA	DFS	Median	All	0.207	0.529	.010	8	view →
LUSC	DFS	Median	All	0.894	0.728	.012	7	view →
SARC	DFS	Median	All	0.097	0.636	<.001	6	view →
LIHC	OS	Median	All	0.162	0.779	<.001	6	view →
SKCM	OS	Median	All	0.913	0.854	.015	6	view →
ACC	DFS	Median	All	0.195	0.748	.003	3	view →
READ	DFS	Median	II,III,IV	1.000	0.458	.038	2	view →

Pink = unfavorable, green = favorable. Showing the 10 strongest of 10 lineages.

THSD7B–PCPG (OS)

Open the PCPG breakdown →